Results 121 to 130 of about 68,565 (138)

CRISPR/Cas9‐edited tumor‐associated immune cells in cancer immunotherapy

VIEW, EarlyView.
Abstract Immuno‐oncology represents an emerging field that has significantly transformed tumor therapeutics, with immune cells serving as the cellular foundations of cancer immunotherapy. Due to its high efficiency and sensitivity, CRISPR/Cas9 genome editing is a highly promising technique for precise and rapid gene modification.
Yuhui Ma, Junxin Chen, Yuan Du, Zhihao Cao, Weizhi Ji, Yuyu Niu, Zebin Yang   +6 more
wiley   +1 more source

Interventional oncology in children: Where are we now?

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel, Fernando Gómez Muñoz   +1 more
wiley   +1 more source

The absence of both RIBC1 and RIBC2 induces decreased sperm motility and litter size in male mice

Andrology, EarlyView.
Abstract Background RIBC1 (RIB43A domain with coiled‐coils 1) and RIBC2 (RIB43A domain with coiled‐coils 2) are homolog proteins of RIB43a which is localized to microtubules in the cilia and flagella of unicellular organisms. Cryo‐electron microscopy and artificial intelligence studies showed that RIBC1 and RIBC2 are microtubule inner proteins (MIPs ...
Kento Katsuma, Keisuke Shimada, Shingo Tonai, Daisuke Mashiko, Rie Iida‐Norita, Yuki Kaneda, Haruhiko Miyata, Masahito Ikawa   +7 more
wiley   +1 more source

Perioperative complications of focal therapy for prostate cancer: results from the GeRmAn Nationwide inpatient Data (GRAND) study

BJU International, EarlyView.
Objective To compare the perioperative complications of the most common focal therapy (FT) modalities for prostate cancer. Patients and Methods We assessed the GeRmAn Nationwide inpatient Data (GRAND) from 2005 to 2023, provided by the Research Data Center of the Federal Bureau of Statistics. We compared perioperative outcomes of high‐intensity focused
Nikolaos Pyrgidis, Michael Chaloupka, Benedikt Ebner, Yannic Volz, Philipp Weinhold, Julian Marcon, Lennert Eismann, Christian G. Stief, Gerald B. Schulz, Maria Apfelbeck   +9 more
wiley   +1 more source

Assessment of Spinster homologue 2 (Spns2)‐dependent transport of sphingosine‐1‐phosphate as a therapeutic target

British Journal of Pharmacology, Volume 182, Issue 9, Page 2014-2030, May 2025.
Abstract Background and Purpose Sphingosine‐1‐phosphate (S1P) receptor modulator (SRM) drugs suppress immune system function by disrupting lymphocyte trafficking, but SRMs are broadly immunosuppressive with on‐target liabilities. Another strategy to modulate the immune system is to block S1P transport.
Yugesh Kharel, Tao Huang, Kyle Dunnavant, Daniel Foster, George M. P. R. Souza, Katherine E. Nimchuk, Andrea R. Merchak, Caitlin M. Pavelec, Zuzanna J. Juskiewicz, Simon S. Alexander, Alban Gaultier, Stephen B. G. Abbott, Jung‐Bum Shin, Brant E. Isakson, Wehao Xu, Norbert Leitinger, Webster L. Santos, Kevin R. Lynch   +17 more
wiley   +1 more source

CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5‐BLTR Signaling Pathway

Cancer Science, Volume 116, Issue 4, Page 1115-1125, April 2025.
We generated cell lines with inducible expression of ASXL1 mutations and found that ASXL1 mutation‐induced cell lines exhibited reduced ABL1 TKI sensitivity. We identified ALOX5 as one of the top upregulated genes under the expression of mutated ASXL1 and high expression of ALOX5 conferring TKI resistance. Inhibition of the ALOX5‐BLTR signaling pathway
Naoki Miyashita, Masahiro Onozawa, Kohei Kasahara, Toshihiro Matsukawa, Yasuhito Onodera, Kohjin Suzuki, Tomoiku Takaku, Takanori Teshima, Takeshi Kondo   +8 more
wiley   +1 more source

Cytoplasmic Vacuolization: A Fascinating Morphological Alteration From Cellular Stress to Cell Death

Cancer Science, Volume 116, Issue 5, Page 1181-1192, May 2025.
This review provides a thorough examination of contemporary studies on cytoplasmic vacuolization in mammalian cells, elucidating its etiology, origins, and molecular pathways. Additionally, it highlights the potential of CVACD as an innovative therapeutic strategy for cancer.
Xiaoxu Wen, Hongru Ma
wiley   +1 more source

Immunosuppressive Effects of Multiple Myeloma‐Derived Extracellular Vesicles Through T Cell Exhaustion

Cancer Science, EarlyView.
Extracellular vesicles (EVs) derived from myeloma cells could potentially induce T cell exhaustion via the increase of the frequency of immune checkpoint marker‐positive CD8+ T cells and might thereby suppress T cell function. In addition, this immune escape mechanism from cytotoxic T cells is supported by the findings on SPHK1/S1P signaling from SPHK1‐
Shinya Hagiwara, Masaki Ri, Toru Ebina, Yoshiaki Marumo, Tomoyuki Nakamura, Kentaro Hirade, Takahiro Nakashima, Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Ayako Masaki, Hirokazu Komatsu, Shinsuke Iida   +13 more
wiley   +1 more source

Ligand‐Based CAR‐T Cells Targeting EGFR Exhibit Favorable Antitumor Effects Against Gynecologic Malignancies

Cancer Science, EarlyView.
Wide variety of gynecologic malignancies express EGFR at high rates. Memory‐rich EGFR CAR‐T cells can be made by piggyBac‐mediated gene transfer with immature dendritic cells and EGFR protein. Ligand‐based EGFR CAR‐T cells have robust antitumor effects against gynecologic malignancies in vivo and in vitro.
Manaka Shinagawa, Koichi Hirabayashi, Marina Fujioka, Kyosuke Kamijo, Natsuki Uchiyama, Yusuke Yokokawa, Yasuhiro Tanaka, Motoki Ono, Thanyavi Chinsuwan, Ryoichi Asaka, Aiko Hasegawa, Miyuki Tanaka, Takashi Murakami, Shigeki Yagyu, Tsutomu Miyamoto, Tanri Shiozawa, Yozo Nakazawa   +16 more
wiley   +1 more source

Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non‐Viral CAR‐NK Cell Engineering

Cell Proliferation, Volume 58, Issue 4, April 2025.
This manuscript provides a comprehensive overview of the state‐of‐the‐art in non‐viral CAR‐NK cell engineering, highlighting its potential to revolutionise cancer treatment. ABSTRACT The recent advancements in cancer immunotherapy have spotlighted the potential of natural killer (NK) cells, particularly chimeric antigen receptor (CAR)–transduced NK ...
Zhaokai Zhou, Yifeng Chen, Yuhao Ba, Hui Xu, Anning Zuo, Shutong Liu, Yuyuan Zhang, Siyuan Weng, Yuqing Ren, Peng Luo, Quan Cheng, Lulu Zuo, Shanshan Zhu, Xing Zhou, Chuhan Zhang, Yukang Chen, Xinwei Han, Teng Pan, Zaoqu Liu   +18 more
wiley   +1 more source